Development of Novel Etodolac Matrix Tablet and their Pharmaceutical Characterization

Abstract

The current work poses a difficulty in producing etodolac oral controlled release tablets using five of the most well-known hydrophilic release rate retardant polymers, including non-toxic materials like HPMC K4M, Carbopol 974, and Eudragit RS100. The batches were created using the wet granulation process. According to the prescribed methods, the pre-and post-compression properties were evaluated. To identify the likely drug release mechanism, the formulations were tested for their capacity to release the drug in the simulated gastric medium. The results were then fitted into several kinetic model(s). The investigation of short-term stability was also carried out. The bulk and tapped densities, which are in the range of 0.85 to 0.86 g/cm3 and 0.95 to 0.98 g/cm3, respectively, show an excellent pre-compression feature. The drug concentration was discovered to be between 98.26%-100.15%. The formulation F3 (102.95%) had the maximum in vitro drug release because it had the ideal concentration of polymer combination, which delayed the drug release and used the diffusion cum erosion process (s). When matrix formulations are carefully fabricated, the frequency of medication administration may be reduced to twice daily while also reducing blood level variations, which ultimately improves patient compliance and therapy regimens.